Accomplished Business Development and Licensing Executive to Drive NTS’s Business Development and Partnering Activities.

NeuroTrauma Sciences today announced that it has commenced dosing in a Phase 1 study of its investigational drug NTS-104, in healthy volunteers.

NeuroTrauma Sciences today announced the expansion of its executive management team with key appointments: Marc de Somer, MD, ScD, MPH, MSc, MBA, has been appointed Chief Medical Officer and Martin Rabe, MSc, joins as Executive Vice President of Regulatory Affairs and Quality Assurance.

The study demonstrated the ability of NTS-105 to reduce cell death at a wide range of concentrations in preclinical models of TBI.

Dr. Parry will discuss recent advances in the development of novel neurosteroids for the treatment of traumatic brain injury.